Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hezbollah field commander killed in IDF strikes in Beirut - 25 Worldwide Road Food varieties You Should Attempt
- 3Artemis II crew cleared to depart Earth orbit, head for moon
- 4Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- 5Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- Thermo Fisher wins contracts as pharma shifts production to US, CEO says
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- Scientists document a death from a meat allergy tied to certain ticks
- 5 Arising Professions in Environmentally friendly power
- Instructions to Warmly greet Certainty and Appeal
- St George Mining hits record 178m high-grade intercept at Araxá, reinforcing global scale
- Top Breakfast Food: What's Your Morning Enjoyment?
- Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
